2型糖尿病中胰高血糖素样肽1受体激动剂试验结果的区域异质性:个体参与者数据的再分析
研究系统检索并纳入6项国际随机对照试验共45426例2型糖尿病患者,按区域计算胰高血糖素样肽1受体激动剂(GLP-1RA)对主要心血管事件(MACE)的风险比(HR),未发现区域间显著异质性(P=0.70),但基线MACE风险较高和较低发展状态与更大获益独立相关。
要点
- 6项试验共45426例患者,MACE的HR在不同区域间无显著异质性(P=0.70)。
- MACE基线风险从南亚的每100患者年2.9至撒哈拉以南非洲的每100患者年7.4。
- 基线MACE风险较高和较低发展状态与GLP-1RA更大获益独立相关。
核心结论
- 本研究未提示GLP-1RA对MACE的疗效存在区域异质性。
- 基线风险较高和较低发展状态与这些药物更大获益相关。
研究设计与样本
- 系统检索Medline和Cochrane Library自建库至2020年6月30日,纳入比较任何GLP-1RA与安慰剂的国际随机对照试验,以MACE为主要终点。
- 纳入6项试验共45426例患者,获取个体参与者数据,按区域计算MACE的HR及95%CI,进行随机效应Meta分析和Meta回归。
主要发现
- MACE基线风险从南亚的每100患者年2.9至撒哈拉以南非洲的每100患者年7.4。
- MACE的HR范围从北非的0.25(95%CI 0.05, 1.12)至西欧的0.98(0.79, 1.22)。
- 区域间无显著亚组差异(P=0.70)。
- 基线MACE风险和发展状态指标(即人类发展指数、国内生产总值)与GLP-1RA疗效独立相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Multiregional trials are designed under the assumption that treatment effect applies to the entire target population, yet several factors may introduce geographic heterogeneity in treatment effect. We explored whether such variations exist in trials assessing the efficacy of glucagon-like peptide 1 receptor agonists (GLP-1RAs) in major cardiovascular events (MACE) in type 2 diabetes. RESEARCH DESIGN AND METHODS: A systematic search of Medline and the Cochrane Library was conducted from inception until 30 June 2020. We included international randomized controlled trials comparing any GLP-1RA versus placebo, with MACE as a primary end point. Individual participant data were subsequently requested from the sponsor or through data sharing platforms. For each trial, we calculated hazard ratios (HRs) and their 95% CIs for MACE, subgrouped by region. We then performed a random-effects meta-analysis and conducted meta-regressions to assess the influence of predetermined variables of interest on treatment effect. RESULTS: We included six trials including 45,426 patients. Baseline risk of MACE ranged from 2.9 per 100 patient-years in Southern Asia to 7.4 per 100 patient-years in Sub-Saharan Africa. HRs for MACE ranged between 0.25 (95% CI 0.05, 1.12) in Northern Africa to 0.98 (0.79, 1.22) in Western Europe. There was no significant subgroup difference across regions (P = 0.70). Baseline risk of MACE and indexes of development status (i.e., Human Development Index, gross domestic product) were independently associated with GLP-1RA efficacy. CONCLUSIONS: This study does not suggest any regional heterogeneity of GLP-1RA efficacy in MACE. However, a higher baseline risk and lower development status were associated with a greater benefit of these drugs.
引用
- Jullien A, Jambon-Barbara C, Cracowski JL, et al. Regional Heterogeneity of the Results of Glucagon-Like Peptide 1 Receptor Agonist Trials in Type 2 Diabetes: A Reanalysis of Individual Participant Data. Diabetes Care. 2024. PMID: 39190488. doi:10.2337/dca24-0034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。